Global Ganja Report

After the first day of Senate confirmation hearings for Jeff Sessions, president-elect Trump's choice to lead the US Justice Department, cannabis advocates are parsing his testimony for clues as to what the incoming administration's stance will be on whether to continue to give breathing room to state-level legalization and medical marijuana laws. The Los Angeles Times takes an ominous view, writing in a headline: "Sessions leaves door open to reviving federal war on pot."

Denver-based AmeriCann is planning to develop what will be the United States' largest medical marijuana facility in Freetown, Mass. At one million square feet, the Massachusetts Medical Cannabis Center is planned for a tract in the Bristol County town formerly slated for a brewery by the Boston Beer Co. Boston Business Journal reports that AmeriCann bought the property this fall for $4.475 million. AmeriCann CEO Tim Keogh said the facility will be "the place in the northeast US for the creation of a wide variety of exciting new advanced products for medical cannabis patients."

The results of the Nov. 8 elections really indicate the schizophrenic nature of American political culture at this moment. Amid the fear and loathing over the election of the fascistic Donald Trump as president, big gains were registered for cannabis freedom. Voters in California approved Proposition 64, legalizing  up to an ounce for those 21 and older, and allowing individuals to grow up to six plants. The measure also permits retail sales and imposes a 15% tax. Similar measures passed in Massachusetts, Maine and Nevada, bringing the percentage of Americans living in states where cannabis is legal for adults up from five to 20 percent. Only Arizona's Proposition 205 was rejected by the voters.

Who do you think is pouring money into the campaigns against the legalization initiaves that will go before the voters in five states next month? Well, an Oct. 22 exposé in The Guardian newspaper will confirm your most cyniical suspicions. In August, the pharmaceutical company Insys Therapeutics became the biggest donor to the campaign to defeat Arizona's Proposition 205, making a $500,000 donation to Arizonans for Responsible Drug Policy (ARDP). In making the donation, Insys cited concerns for child safety. But The Guardian points out the delicious irony: Insys manufactures Subsys, a prescription painkiller derived from fentanyl—a synthetic opioid that is up to 100 times more powerful than morphine. And the Phoenix New Times adds that Insys is under investigation in four states, including Arizona, for marketing practices related to Subsys that have allegedly resulted in patient deaths.

Is the alcohol industry spending money to get members of Congress to pay attention to the problem of "marijuana-impaired driving"? That's the case made on the cannabis industry website Marijuana.com, where a blogger seems to have assiduously searched the famous WikiLeaks dump of DNC e-mails for any reference to our favorite herb. What they found was in the May 24, 2016 edition of Huddle, a daily e-newsletter for Capitol Hill insiders produced by the Politico website. That issue included a paid advertisement from the Wine & Spirits Wholesalers of America (WSWA), which read in part:

As Canada prepares to legalize cannabis nationwide, Ottawa is consulting citizens and stake-holders to shape the new policy. Among the proposals floated at a Vancouver Cannabis Hemp Conference this weekend was a measure to cap the THC content of approved strains. Not surprisingly, this met with a resounding negative from industry and advocates. "It's time for us to stop demonizing THC. We need policy that's based on both evidence and expertise," Hilary Black of the BC Compassion Club Society told the CBC.  "We have an opportunity in Canada right now to be leaders on the world stage and to do this right."

"Colorado teens stubbornly refuse to smoke more weed." That's the smart-alecky headline over a chart of youth cannabis use rates that appeared in the Washington Post June 21. The story cites Colorado Health Department findings that rates of use among the state's teenagers are essentially unchanged in the years since the herb was legalized there in 2012. In last year's figures, 21% of Colorado youths had used cannabis in the past 30 days. That is slightly lower than the national average, and down from 25% in 2009. The findings are based on a random survey of 17,000 middle and high school students. "The survey shows marijuana use has not increased since legalization, with four of five high school students continuing to say they don’t use marijuana, even occasionally," the health department stated.

For a second year running, the US Border Patrol reports drastically reduced cannabis seizures along the Mexican border—and even the mainstream media can't help making the connection to the growing trend toward legalization and tolerance in the United States. In reporting the findings, the Washington Post uses the headline, "Legal marijuana is finally doing what the drug war couldn't." Last year, border agents confiscated some 1.5 million pounds—down from a peak of nearly 4 million in 2009. Increased domestic production in California, Colorado and Washington have driven prices down, especially at the bulk level. "Two or three years ago, a kilogram [2.2 pounds] of marijuana was worth $60 to $90," a Mexican cannabis farmer recently told NPR. "But now they're paying us $30 to $40 a kilo. It's a big difference. If the U.S. continues to legalize pot, they'll run us into the ground."